CEO Executive AssistantDeveloping medicines for children is among the most ethically demanding and operationally complex endeavors in pharmaceuticals. Pediatric drug development involves distinct scientific challenges, regulatory requirements that differ substantially from adult drug development, and commercial models built around small patient populations and specialty distribution. For CEOs of pediatric-focused pharmaceutical and biotech companies, the stakes - measured in the health and wellbeing of children who often have no other treatment options - could not be higher.
This framework outlines how pediatric pharma CEOs can build a delegation architecture that enables expert teams to execute across clinical, regulatory, medical, and commercial functions, while the CEO provides the strategic leadership and external representation that the organization requires.
The Pediatric Pharma CEO’s Delegation Context
Pediatric pharmaceutical companies face a distinctive set of organizational demands. Many operate in rare pediatric disease segments, where patient populations are measured in the hundreds or thousands globally. Clinical trial design must account for pediatric-specific pharmacokinetics, formulation requirements, and age-appropriate endpoints. Regulatory strategy must navigate the Pediatric Research Equity Act, Written Requests under BPCA, rare pediatric disease priority review vouchers, and - for applicable programs - orphan drug designations.
The commercial environment is defined by specialty pharmacy distribution, intensive patient support programs, and pricing models that must justify high list prices to payers while ensuring that no child is denied access for financial reasons. The advocacy environment includes parents and caregiver communities who are deeply engaged with the companies developing treatments for their children’s conditions.
All of these functions require specialized expertise. According to research from Harvard Business Review, leaders who delegate effectively to expert teams consistently outperform those who maintain centralized control. For pediatric pharma CEOs, this is not simply a productivity observation - it is an ethical imperative. These patients deserve the full depth of organizational expertise at every functional level.
Clinical Development Delegation
Pediatric clinical development requires specialized expertise in pediatric pharmacology, age-appropriate trial design, formulation development, and ethical trial oversight. CEOs should not be operationally involved in these specialized functions.
What to delegate:
- Pediatric protocol development (extrapolation from adult data, de novo pediatric trial design)
- Age-appropriate formulation development coordination
- Site selection and investigator engagement (including centers with pediatric clinical trial expertise)
- Patient enrollment strategy for small population trials
- Pediatric data safety monitoring committee oversight
- Age-stratified pharmacokinetic and pharmacodynamic analysis
- Clinical operations and CRO management
To whom: Chief Medical Officer or VP of Clinical Development, with a dedicated Pediatric Clinical Development lead who has specific expertise in pediatric pharmacology and trial design.
What the CEO retains: Stage gate decisions at major program milestones, portfolio decisions about pediatric indication prioritization, and major partnership decisions affecting the clinical pipeline.
Regulatory Affairs Delegation
Pediatric regulatory strategy is distinct and requires specialists who understand the full toolkit of pediatric regulatory mechanisms, including written requests, study orders, PREA requirements, rare pediatric disease vouchers, and the pediatric review processes at FDA’s Office of Pediatric Therapeutics.
What to delegate:
- Pediatric Study Plans and initial pediatric study requests
- Written Request and PREA compliance management
- IND, NDA, and BLA preparation and submission
- Rare pediatric disease designation and priority review voucher strategy
- Advisory committee preparation and facilitation
- Labeling negotiations for pediatric populations
To whom: Chief Regulatory Officer or VP of Regulatory Affairs, with a pediatric regulatory specialist on the team.
What the CEO retains: Relationship with FDA pediatric leadership, strategic decisions about regulatory pathway choices with major commercial implications, and priority review voucher strategic decisions (sale, use, or partnership).
Priority review vouchers are uniquely high-value regulatory assets for pediatric pharma companies. The strategic decision about whether to sell, use, or partner a voucher is a CEO-level decision that carries significant financial implications. The regulatory team manages the voucher qualification and designation process; the CEO decides what to do with the asset.
The pharma CEO guide provides a foundational framework for how pharma CEOs can structure regulatory and other functional delegation across the enterprise.
Medical Affairs and Patient Community Relations
Medical affairs in pediatric pharma has unique dimensions. The community of physicians treating pediatric rare diseases is small and highly networked. Parent and caregiver advocacy is intense and well-organized. Medical affairs must navigate both the clinical community and the patient advocacy ecosystem with sensitivity and expertise.
What to delegate:
- KOL identification and engagement (pediatric subspecialists, metabolic disease centers, children’s hospitals)
- Investigator-initiated study review and funding
- Medical education program development
- Medical information management
- Health outcomes and quality-of-life research
- Patient advocacy organization relationship management (day-to-day)
To whom: VP of Medical Affairs, with a patient advocacy director for community relations.
What the CEO retains: Personal relationships with the CEOs and most prominent leaders of the relevant patient advocacy organizations, final decisions on major publication strategies, and participation in disease-specific scientific symposia as a visible organizational leader.
Commercial and Market Access Delegation
Pediatric pharmaceutical commercial strategy is built around specialty distribution, patient support programs, and highly individualized payer engagement. Given small patient populations, every patient matters commercially and ethically.
What to delegate:
- Patient identification and diagnosis support programs
- Specialty pharmacy program management
- Patient access and copay assistance program administration
- Payer contracting and coverage determination support
- Key account management (children’s hospitals, academic medical centers)
- Marketing communications and disease awareness programs
To whom: Chief Commercial Officer or VP of Commercial, with dedicated patient access and market access leads.
What the CEO retains: Major pricing decisions, outcomes-based contracting strategy, investor-facing commercial narrative, and decisions about access programs that balance sustainability with the company’s commitment to patient access.
The ethical dimension of pricing and access in pediatric rare diseases is particularly acute. The CEO must personally own the access philosophy and ensure it is embedded in commercial decision-making, even while delegating operational access program management.
For more detailed guidance on delegating commercial operations in pharma, the pharma commercial strategy guide provides a comprehensive treatment of commercial delegation across the product lifecycle.
Pediatric-Specific Delegation Considerations
Expanded access and compassionate use. Pediatric pharma companies receive frequent requests for expanded access from desperate families whose children have no other options. A clear expanded access policy - developed with input from clinical, regulatory, medical affairs, and legal teams, and approved by the CEO - allows the medical team to make decisions within a framework without escalating every case to the CEO. The CEO sets the policy; the medical team implements it.
Caregiver and parent community engagement. Parent advocacy communities in pediatric rare diseases are uniquely engaged and often deeply involved in clinical trial design, endpoint selection, and company strategy. The CEO’s engagement with these communities should be personal and authentic, not fully mediated through staff. A quarterly CEO touchpoint with major patient advocacy organization leadership is appropriate.
Scientific advisory board for pediatric expertise. Because the pool of pediatric specialists in rare diseases is small, a well-constituted scientific advisory board provides access to expertise that the company may not be able to hire full-time. The CMO or CSO manages the scientific advisory board operationally; the CEO participates in key meetings as a strategic and relationship investment.
Formulation development. Age-appropriate formulation (palatability, dosing flexibility, drug delivery mechanism) is often as critical as efficacy in pediatric drug development. The CEO should understand the formulation strategy at a high level but delegate all technical decision-making to the CMC and clinical pharmacology teams.
Governance Rhythm for Pediatric Pharma CEOs
- Monthly: Pipeline review with CMO (program status, enrollment, regulatory milestones), regulatory briefing with CRO
- Quarterly: Commercial performance review, patient access program review, patient advocacy engagement update
- Semi-annually: Scientific advisory board meeting (CEO participates in strategic session)
- Annually: Portfolio strategy review, organizational design assessment
Building the Right Team
Pediatric pharmaceutical organizations must attract functional leaders with genuine pediatric expertise. The CMO should have pediatric clinical development experience. The CRO should understand FDA’s pediatric regulatory mechanisms. The medical affairs team should include specialists who understand pediatric subspecialty communities.
These candidates are scarce, and recruiting them requires competitive compensation, a compelling mission, and a CEO who creates the organizational conditions that allow functional leaders to do their best work - including giving them genuine authority and not second-guessing every decision.
Conclusion
Pediatric pharmaceutical companies carry an extraordinary responsibility: developing medicines for children who have no other options and for the families who love them. Meeting this responsibility requires organizational excellence at every functional level, which in turn requires a CEO who delegates effectively to expert teams with full authority.
The pediatric pharma CEO’s role is to set the strategic vision, ensure the organization has the resources and talent to execute, build the partnerships and relationships that advance the pipeline, and represent the company to investors, partners, and the patient community. That is work enough for one person. The rest must be delegated.
Related Reading
For further context, explore Delegation Framework for the 3PL Provider CEO and Delegation Framework for Academic Medical Center CEO.